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Two histopathological subtypes of Meniere’s disease (MD) were recently described in a
human post-mortem pathology study. The first subtype demonstrated a degenerating
distal endolymphatic sac (ES) in the affected inner ear (subtype MD-dg); the second
subtype (MD-hp) demonstrated an ES that was developmentally hypoplastic. The
two subtypes were associated with different clinical disease features (phenotypes),
suggesting that distinct endotype-phenotype patterns exist among MD patients.
Therefore, clinical endotyping based on ES pathology may reveal clinically meaningful
MD patient subgroups. Here, we retrospectively determined the ES pathologies of clinical
MD patients (n= 72) who underwent intravenous delayed gadolinium-enhanced inner ear
magnetic resonance imaging using previously established indirect radiographic markers
for both ES pathologies. Phenotypic subgroup differences were evidenced; for example,
the MD-dg group presented a higher average of vertigo attacks (ratio of vertigo patterns
daily/weekly/other vs. monthly, MD-dg: 6.87: 1; MD-hp: 1.43: 1; p = 0.048) and more
severely reduced vestibular function upon caloric testing (average caloric asymmetry
ratio, MD-dg: 30.2% ± 30.4%; MD-hp: 13.5% ± 15.2%; p = 0.009), while the MD-hp
group presented a predominantly male sex ratio (MD-hp: 0.06:1 [f/m]; MD-dg: 1.2:1
[f/m]; p = 0.0004), higher frequencies of bilateral clinical affection (MD-hp: 29.4%;
MD-dg: 5.5%; p = 0.015), a positive family history for hearing loss/vertigo/MD (MD-hp:
41.2%; MD-dg: 15.7%; p = 0.028), and radiographic signs of concomitant temporal
bone abnormalities, i.e., semicircular canal dehiscence (MD-hp: 29.4%; MD-dg: 3.6%;
p = 0.007). In conclusion, this new endotyping approach may potentially improve the
diagnosis, prognosis and clinical decision-making for individual MD patients.
Keywords: endolymphatic sac, patient subgroups, phenotype, degeneration, hypoplasia
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INTRODUCTION
A major challenge in diagnosing and managing patients with
Meniere’s disease (MD) is its heterogeneous clinical presentation
(i.e., phenotypic differences among patients) (1). For example,
vestibular and auditory symptoms may occur together or in a
temporally independent manner, in varying frequency patterns
(e.g., daily, monthly, episodically), and with some symptoms
predominating over others (e.g., more pronounced vestibular
than auditory symptoms) (2, 3). Symptom attacks may occur
in response to identifiable triggers [e.g., high sodium intake,
caffeine, stress, reviewed in (1, 4)] or in random patterns. Inmany
cases, the disease remains unilateral (one inner ear clinically
affected), whereas progression to bilateral disease is observed in
∼40% of cases (2, 5). In the long-term, the degree of permanent
hearing loss and vestibular hypofunction can remain mild to
moderate or progress to severe levels (2). Identifying distinct
phenotypic patterns among MD patients would potentially
enable clinicians to predict clinical features or the disease course
in individual MD patients.
In a recent post-mortem histopathology study on inner ear
tissues fromMD patients (6), we identified two histopathological
subtypes of the disease: (i) epithelial degeneration of the
endolymphatic sac (ES) and (ii) organ hypoplasia of the
ES. Both ES pathologies result in loss of the normal ES
epithelium and its ion transport functions. Loss of ES function
presumably underlies the endolymphatic hydrops generation in
MD and is believed to be a necessary precondition for MD’s
clinical symptomatology. We therefore consider the two ES
pathologies to be etiopathologically distinct MD “endotypes”
that may be associated with different phenotypical features. To
investigate endotype-phenotype patterns in clinical patients, we
previously developed a high-resolution computed tomography
(HRCT)-based imaging method to distinguish the two ES
pathologies (7).
The present study aimed to (i) adapt the method to
distinguish ES pathologies based on gadolinium-enhanced
magnetic resonance imaging (Gd-MRI); (ii) retrospectively
subgroup a series of MD patients based on their ES pathology;
and (iii) investigate, based on clinical data, whether these
endotypes separate into clinically meaningful patient subgroups.
METHODS
Study Design and Approval
This retrospective explorative study was approved by the
local Ethics Committee (application KEK-ZH-Nr. 2016-
01619, Kantonale Ethikkommission, Zurich, Switzerland) in
accordance with the Helsinki declaration and its amendments.
Written informed general consent was obtained from
all participants.
Study Population
We retrospectively assessed consecutive patients who attended
our interdisciplinary center for vertigo and balance disorders
at the University Hospital Zurich (tertiary referral center) from
January 2010 to December 2015 for eligibility to be included in
the study. The inclusion criteria were available data from Gd-
MRI of the inner ears [(8); n= 187] and a final diagnosis of uni or
bilateral definite MD [(9); n = 92]. We excluded patients with a
Meniere’s-like symptom complex due to a secondary pathology
[e.g., otosclerosis, vestibular schwannoma, history of temporal
bone fracture, and Cogan’s syndrome, reviewed in (10)], patients
who fulfilled the diagnostic criteria for possible or probable
MD (9), and patients who were ultimately assigned another
vertigo-associated diagnosis (e.g., vestibular migraine). Of the 92
primarily included MD patients, 20 were excluded after Gd-MRI
data analysis (see “Vestibular aqueducts (VA) measurements and
patient endotyping”). Finally, 72 patients’ data were statistically
analyzed (Figure 1).
Temporal Bone Imaging
During the routine clinical work-up, patients underwent 3-T MR
imaging of the temporal bones 4 h after intravenous contrast
(Gd) was administered to detect endolymphatic hydrops based
on previously established protocols (8, 11). The endolymphatic
hydrops grade (8) and signs of semicircular canal (SCC)
FIGURE 1 | Study flowchart. MD was definitively diagnosed per the guidelines
from the Committee on Hearing and Equilibrium of the American Academy of
Otolaryngology-Head and Neck Surgery for the Definition of Meniere’s Disease
from 1995 (9). VA bending angles and clinical chart reviews were assessed in a
blinded manner (see text for details). *according to Merchant and Nadol (10).
(Gd-MRI, gadolinium-enhanced magnetic resonance imaging; ES,
endolymphatic sac; MD, Meniere’s disease; VA, vestibular aqueduct).
Frontiers in Neurology | www.frontiersin.org 2 April 2019 | Volume 10 | Article 303
Bächinger et al. Endotype-Phenotype Patterns in Meniere’s Disease
dehiscence (i.e., absence of low-signal bone margins around the
SCCs) were evaluated by experienced neuroradiologists at the
time the images were taken. Additional dedicated temporal bone
HRCT imaging was available for a subset of patients (n = 16).
HRCT data were reconstructed separately for each temporal bone
in the axial plane using a standard bone algorithm.
Vestibular Aqueduct (VA) Measurements
and Patient Endotyping
We recently established amethod to clinically distinguish the two
histopathological subtypes (ES degeneration vs. ES hypoplasia)
using the vestibular aqueduct angular trajectory (ATVA) as a
radiographic surrogate marker (7). We demonstrated that the
two ES pathologies are associated with significantly different
VA bending angles (αexit), which can be reliably determined
using temporal bone HRCT imaging data and custom-developed
software (12). Here, we validated the method for use with the
Gd-MRI data by performing αexit measurements based on HRCT
and Gd-MRI (T2 space or 3D inversion recovery sequence) data
from the same MD patients (n = 16). The imaging datasets
were presented to an investigator (DB) who performed all
measurements in a randomized order. The measured angles
revealed a strong intermodal correlation between the HRCT
and Gd-MRI (Spearman correlation coefficient r = 0.95, p <
0.0001; Figure 2).
Previously determined reference values for αexit were used
to endotype the MD patients (7). In clinically affected inner
ears, angles ≤120◦ indicated a degenerative ES pathology. This
subgroup is hereafter referred to as “MD-dg” patients. Angles
≥140◦ indicated a hypoplastic ES pathology, hereafter referred
to as “MD-hp” patients. Of the 92 patients whose Gd-MRI-based
ATVA was measured, 20 were excluded from the final analysis
FIGURE 2 | CT vs. Gd-MRI correlation for αexit. Angles were measured from
HRCT and Gd-MRI data from the same 16 MD patients.
because of inconclusive αexit values (>120
◦ and<140◦) likely due
to insufficient image quality from the Gd-MRI data.
Reproducibility of the ATVA Measurements
Internal consistency of the Gd-MRI-based angle measurements
and patient endotyping was tested by two independent
investigators (AE and DB) who reassessed the Gd-MRI data from
a randomly selected 14% of the cases. The investigators were
blinded to the previous measurements when remeasuring αexit
and assigning cases to the endotype subgroups per the procedures
described above. The interobserver test-retest reliability of the
endotype assignments (MD-dg vs. MD-hp) was determined
using Cohen’s kappa coefficient (x). A x-value of 0.78 was
determined, indicating excellent test-retest agreement per (13).
Clinical Data Collection and Processing
Clinical records, audiometric and vestibular test data, and
radiology reports were reviewed by two investigators (CB and
TH), who were blinded to the original imaging data and
endotyping results. All data were collected in a structured
digital database with predefined variables and categories. After
collecting the data, all variables in the database were checked
for categories with excessively low cell frequencies (<4). Those
categories were merged with others from the same variable based
on clinical meaningfulness to retain sufficient statistical power.
Statistical Analysis
Null hypotheses were formulated and statistical tests were
selected before collecting the data. Second-step statistical analysis
(post hoc testing) was clearly indicated (see respective paragraph).
For binary variables, a chi-square test was performed if all
category frequencies were greater than five; otherwise, Fisher’s
exact test was performed. Continuous variables were analyzed
using a two-tailed Student’s t-test for independent samples
if the data were normally distributed; otherwise, a two-tailed
Mann-Whitney U-test was performed. If not otherwise specified,
statistical analyses were performed using IBM SPSS Statistics,
version 24 (IBM Corp., Armonk, NY, USA). P-values were
categorized into levels of evidence against H0 (very strong
evidence, p < 0.001; strong evidence, p = 0.001–0.01; evidence,
p = 0.01–0.05; weak evidence, p = 0.05–0.1; and little or no
evidence, p > 0.1) per (14).
Multiple Testing Correction
Twenty-eight independent null hypotheses were tested on the
sample data. (A Benjamini–Hochberg procedure for multiple
comparisons was used to control the false discovery rate (FDR)
(15) see also the following paragraph). Subsequent p-values
are followed by a statement regarding their significance per
the Benjamini-Hochberg procedure (significant [sig.] or not
significant [n. s.]) (16).
Rationale for Choosing the FDR’s Critical
Value
This study’s purpose was to exploratively and exhaustively screen
for clinical variables that differed between the two predefined
patient subgroups and that would potentially contribute to the
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variable’s clinical meaningfulness. Therefore, in our statistical
analysis, we intended to minimize the risk of false negatives (type
II error) while retaining an appropriate risk of false positives
(type I error), which was controlled by the FDR (15). In contrast
to large-scale multiple-testing studies (e.g., genomics studies
with >103 null hypotheses) that typically apply an FDR of 0.05
to minimize the type I error probability, we chose an FDR
of 0.15. This value is associated with a reduced type II error
rate and is commonly used in explorative and proof-of-concept
studies (17, 18) in which not overlooking any true-positive results
is prioritized.
Post hoc Analysis
In all contingency tables where significant differences were
detected (based on an FDR of 0.15) between the groups, we
performed post hoc testing per (19), enabling rigorous control of
type I error rates: all three possible pairwise comparisons were
performed between one variable and the other two, followed by
a Bonferroni correction (in which the p-value is divided by the
number of tests).
Longitudinal Analysis
To investigate whether the twoMD endotypes differed in hearing
loss progression over time (i.e., the slope of pure-tone averages
[PTAs] respective of time), we performed a longitudinal analysis
on data from each patient’s repeated audiometric measurements.
In bilateral cases, each ear was considered a separate case.
A linear mixed-effects model was used with a subject-specific
random intercept and a random slope for time. This model
enabled varying baseline measurements and time-varying trends
among subjects, considering data imbalance and unequal time-
spacing. PTA measurements constituted the response, while
time and endotype were the explanatory variables. Moreover, an
interaction term between pathology type and time was included
in the model to allow a pathology-specific time trend. The
longitudinal analysis was performed in the R programming
language using the function, lmer(), from the analysis-specific
package, lme4 (20, 21).
Volume Reconstructions
Inner ear volumes (Figure 3) were reconstructed from Gd-MRI
data using 3D Slicer software [version 4.8.1 for Mac OS X (22)].
FIGURE 3 | Gd-MRI VA morphology in representative MD cases with degenerative (A,B) and hypoplastic (C,D) ES pathology. Maximum intensity projections of axial
plane images (A,C), and 3D reconstructions (postero-superior view) of the labyrinthine fluid spaces with the VA shown in magenta (B,D). Arrowheads in (A,C) indicate
the VA in the opercular region. Insets in (A,C) show angle measurements of the VA’s angular trajectory as described previously (7) (sSCC, superior semicircular canal;
hSCC, lateral semicircular canal; pSCC, posterior semicircular canal). Scale bars, 10mm.
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TABLE 1 | Key baseline characteristics of the study sample.
Total MD patients included (n = 72)
Female:male ratio 41 (56.9%): 31 (43.1%)
Unilateral:bilateral ratio 64 (88.9%): 8 (11.1%)
Disease duration (*) 10.1 (6.1) years
Age at first MD symptoms 46.8 (12.0) years
Age at inclusion 56.8 (12.7) years
Mean (SD) or absolute numbers (percentage). *Mean disease durations at inclusion were
similar in both subgroups (MD-dg: 9.8 ± 6.4 years MD-hp: 10.6 ± 5.1 years; p = 0.685).
RESULTS
Patient Endotyping and Baseline
Characteristics
Of the 72 patients who were ultimately included, 55 (76.4%)
demonstrated angles (αexit) ≤120
◦ in the clinically affected
inner ear(s). This subgroup was histopathologically diagnosed
with ES degeneration (6) and is hereafter referred to as
the MD-dg subgroup (Figures 3A,B). In 17 patients (23.6%),
angles (αexit) ≥140
◦ were observed, corresponding to a
histopathological diagnosis of ES hypoplasia [(7); MD-hp
subgroup; Figures 3C,D]. Table 1 shows the 72 endotyped
patients’ baseline characteristics.
Between-Endotype Clinical Differences
From 28 clinical variables (Table 2), seven variables showed
evidence to very strong evidence (14) for group differences (MD-
dg vs. MD-hp endotypes), which are highlighted together with
other potentially clinically meaningful variables (Figure 4).
Very strong evidence was found for a different sex distribution
(p = 0.0004, sig.; Figure 4A), with a strong preponderance
of male patients in the MD-hp group (male-to-female ratio
= 1:0.06) and a nearly balanced male-to-female ratio in the
MD-dg group (1:1.2). The Gd-MRI data strongly evidenced
radiological signs of SCC dehiscence (Figure 4B; i.e., no clear
spatial separation of signals from the superior, posterior or
both SCCs and the cerebrospinal fluid space) more often in
the MD-hp group (5/17 [29.4%]) than in the MD-dg group
[2/55 [3.6%]; p = 0.007, sig.]. The objective vestibular test data
strongly evidenced, on average, greater reductions of bithermal
caloric responses (Figure 4C) on the clinically affected side in
the MD-dg group (30.2 ± 30.4% asymmetry, n = 48) than
in the MD-hp group (13.5 ± 15.2% asymmetry, n = 12; p
= 0.009, sig.). Notably, there was no evidence that the mean
age at caloric testing differed between groups (MD-dg group:
54.9 ± 13.5 years; MD-hp group 52.4 ± 8.7 years, p = 0.38).
We found further evidence for a higher frequency of bilateral
clinical manifestations (Figure 4D) in the MD-hp group (5/17
[29.4%]) than in the MD-dg group (3/55 [5.5%]; p = 0.015,
sig.), as well as for different frequency patterns of vertigo
symptoms (Figure 4E) between groups (p = 0.023, sig.). Post
hoc comparisons (Table 3) evidenced a group difference when
testing the frequency pattern “monthly” (MD-dg: 12.7%, MD-
hp: 41.2% of patients) vs. the other two frequency patterns
(“daily/weekly” and “less than once per month”; p = 0.048,
Bonferroni corrected). Although the initial analysis revealed no
evidence of group differences regarding a positive family history
for MD, non-age-related hearing loss or vertigo and migraine
(Figure 4F), post hoc analysis for MD and hearing loss/vertigo
symptoms only (Table 3) was more prevalent in relatives of MD-
hp patients (41.2%; MD-dg group: 15.7%, data available from n
= 51; p= 0.028, Bonferroni corrected).
For the remaining variables, no evidence of group differences
was found, or no statistical analysis was performed. Those
variables nonetheless represent clinically meaningful and
potentially endotype-segregating features (see Discussion
section). Although strong evidence suggested that headache
symptom frequencies differed between the two groups in
the primary statistical analysis (p = 0.004, sig., Table 2),
post hoc analysis (Table 3) revealed no evidence of a group
difference when only male patients in both groups were
compared to eliminate sex as a confounding factor [higher
prevalence of migraine headaches in women than in men in
the general population (23)]. In the MD-hp group, unilateral
hypoplastic ES pathology was invariably associated with
ipsilateral endolymphatic hydrops and ipsilateral MD. However,
among the eight patients with bilateral ES hypoplasia, five
demonstrated endolymphatic hydrops and MD symptoms
in both inner ears, while three had only one ear affected
(Figure 4G). The mean age when MD symptoms first manifested
was slightly earlier in the MD-hp group (43.1 ± 8.9 years)
than in the MD-dg group (47.9 ± 12.6 years; p = 0.152, n. s.;
Figure 4H). Endolymphatic hydrops without evidence of clinical
affection [i.e., “clinically silent” endolymphatic hydrops (8, 24)]
was exclusively observed in the contralateral inner ears from
unilaterally affected MD-dg patients (19.2% of patients; p =
0.186, n. s.; Figure 4I).
DISCUSSION
The following sections discuss the endotype-specific clinical
characteristics and their potential implications for clinically
managing MD patients (synopsis in Table 4).
Endotype “ES Hypoplasia” (MD-hp
Subgroup)
ES hypoplasia was present in 23.6% of our cohort.
Unilateral ES hypoplasia was invariably associated with
ipsilateral endolymphatic hydrops and MD but not with any
radiological/clinical signs for contralateral affection. In those
cases, the risk of developing MD in the contralateral inner ear
(normal VA angle) is probably low, most likely comparable
to the risk of MD with an ES degenerative endotype in the
general population [i.e., ∼0.15% per a calculation based on
data from this study and (26)], and they may be suitable
candidates for ablative therapies [e.g., gentamicin injections)
in the affected ear if clinically indicated. MD-hp patients
should be considered with caution for ES surgical procedures
[decompression, shunting, or endolymphatic duct blockage;
reviewed in (28, 29)] since the hypoplastic operculum of the
VA is considerably smaller than normal, and the extraosseous
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TABLE 2 | Demographic and clinical characteristics tested for between-group differences.
Variable Degeneration (n = 55) Hypoplasia (n = 17) Difference (95% CI) p-value Benjamini-
Hochberg
significance
Female:male ratio 30 (54.5%): 25 (45.5%) 1 (5.9%): 16 (94.1%) n. a. 0.0004 sig.
Headache type
- Migraineous 20 (36.4%) 4 (23.5%)
- Non-migraineous 5 (9.1%) 8 (47.1%) n. a. 0.004 sig.
- None 30 (54.5%) 5 (29.4%)
SCC dehiscence on affected side 2 (3.6%) 5 (29.4%) n. a. 0.007 sig.
Caloric response asymmetry
(unilateral cases)—% asymmetry
30.2 ± 30.4 (n = 48) 13.5 ± 15.2 (n = 12) 16.7 (4.4 to 29.1) 0.009 sig.
Laterality
- Unilateral 52 (94.5%) 12 (70.6%) n. a. 0.015 sig.
- Bilateral 3 (5.5%) 5 (29.4%)
Vertigo frequency
- Daily/weekly 36 (65.5%) 9 (52.9%)
- Monthly 7 (12.7%) 7 (41.2%) n. a. 0.023 sig.
- Other 12 (21.8%) 1 (5.9%)
Family history
- MD 2 (3.6%) 2 (11.8%)
- Hearing loss/vertigo 6 (10.9%) 5 (29.4%)
- Migraine 6 (10.9%) 0 (0.0%) n. a. 0.141 n. s.
- None 37 (67.3%) 10 (58.8%)
- No data 4 (7.3%) 0 (0.0%)
Age at first symptoms 47.9 ± 12.6 43.1 ± 8.9 4.8 (−0.8 to 10.3) 0.152 n. s.
Cardiovascular comorbidities 20 (36.4%) 3 (17.6%) n. a. 0.234 n. s.
Hearing aid(s) 20 (36.4%) 9 (52.9%) n. a. 0.265 n. s.
Vegetative symptoms 47 (85.5%) 12 (70.6%) n. a. 0.277 n. s.
Hydrops grade—median (25th−75th percentiles) 1.3 (1.0 to 2.0) 1.0 (0.9 to 1.5) n. a. 0.289 n. s.
oVEMP asymmetry ratio 6.5 ± 24.3 (n = 41) 13.0 ± 19.4 (n = 13) 6.5 (−7.1 to 20.0) 0.324 n. s.
cVEMP asymmetry ratio 6.9 ± 22.4 (n = 38) 15.8 ± 22.8 (n = 13) 8.9 (−0.5 to 14.2) 0.333 n. s.
Dynamic visual acuity loss (logMAR)—median
(25th−75th percentiles)
0.4 (0.5 to 0.6) (n = 40) 0.3 (0.4 to 0.6) (n = 7) n. a. 0.349 n. s.
Hearing loss (last PTA)—median (25th−75th
percentiles)
40.0 (19.9 to 54.6) 42.1 (26.8 to 42.1) n. a. 0.403 n. s.
Head impulse test gain ratios—median (25th−75th
percentiles)
1.1 (0.9 to 1.3) (n = 49) 1.0 (0.8 to 1.3) (n = 9) n. a. 0.410 n. s.
Neck or spine problems 9 (16.4%) 1 (5.9%) n. a. 0.434 n. s.
Hearing loss (first PTA)—median (25th−75th
percentiles)
28.3 (10.8 to 45.5) 28.25 (19.3 to 44.4) n. a. 0.443 n. s.
Maximal MD therapy
- Betahistine/cinnarizine 17 (30.9%) 6 (35.3%)
- Intratympanic dexamethasone/lidocaine 34 (61.8%) 11 (64.7%) n. a. 0.665 n. s.
- Intratympanic gentamicin 4 (7.3%) 0 (0.0%)
Photo-/phono-phobia 17 (30.9%) 6 (35.3%) n. a. 0.735 n. s.
Hearing loss pattern (first PTA)
- Low 6 (10.9%) 0 (0.0%)
- High and low (peak) 25 (45.5%) 9 (52.9%)
- High/other 9 (16.4%) 3 (17.6%) n. a. 0.737 n. s.
- All frequencies 13 (23.6%) 5 (29.4%)
- No hearing loss 2 (3.6%) 0 (0.0%)
Migraineous aura 11 (20.0%) 3 (17.6%) n. a. 0.830 n. s.
(Continued)
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TABLE 2 | Continued
Variable Degeneration (n = 55) Hypoplasia (n = 17) Difference (95% CI) p-value Benjamini-
Hochberg
significance
Maximal migraine therapy
- Magnesium, vitamin B2, flunarizine 13 (23.7%) 4 (23.5%)
- Valproate, triptans 10 (18.1%) 4 (23.5%) n. a. 0.928 n. s.
- None 32 (58.2%) 9 (52.9%)
Hearing loss pattern (last PTA)
- Low 1 (1.8%) 0 (0.0%)
- High and low 17 (30.9%) 6 (35.3%)
- High/other 10 (18.2%) 2 (11.8%) n. a. 0.929 n. s.
- All frequencies 23 (41.8%) 8 (47.1%)
- No hearing loss 3 (5.5%) 0 (0.0%)
- No data 1 (1.8%) 1 (5.9%)
First MD symptom
- Hearing loss 13 (23.6%) 4 (23.5%)
- Vertigo 11 (20.0%) 5 (29.4%)
- Tinnitus/aural fullness 5 (9.1%) 1 (5.9%) n. a. 0.929 n. s.
- Multiple 21 (38.2%) 7 (41.2%)
- No data 5 (9.1%) 0 (0.0%)
Allergies 6 (10.9%) 2 (11.8%) n. a. 0.992 n. s.
Vertigo quality
- Rocking 12 (21.8%) 4 (23.5%)
- Spinning 41 (74.6%) 13 (76.5%) n. a. 1.000 n. s.
- Other 2 (3.6%) 0 (0.0%)
Values are reported as absolute numbers (percentage), mean ± SD or median with 25th and 75th percentiles. The number in brackets indicates the number of patients included in the
analysis if some patients in the group were excluded. 95% CI, 95% confidence interval; cVEMP/oVEMP, cervical/ocular vestibular-evoked myogenic potentials; logMAR, logarithm of
minimum angle of resolution; MD, Meniere’s disease; n. a., not applicable; n. s., not significant; PTA1, first available pure-tone audiometry; PTA4, last available pure-tone audiometry;
SCC, semicircular canal; sig., significant.
ES portion is mostly absent (6). A recent retrospective study
showed that during ES surgery in MD patients, intraoperatively
visualizing the operculum was impossible in 28% of the cases
(25). This number very closely matches the hypoplastic ES-
endotype prevalence found in the present study (23.6%). In
almost all MD-hp patients, bilateral ES hypoplasia was associated
with bilateral endolymphatic hydrops and MD; however, three
of those patients showed only unilateral hydrops and clinical
symptoms at the time of data collection (Figure 4G). These
three patients are expected to develop bilateral MD later in life
based on the consistent association between ES hypoplasia and
clinical symptoms that we found previously in post-mortem
cases (6, 7). Thus, in all MD-hp patients with bilateral ES
hypoplasia, a bilaterally impaired audiovestibular function
(bilateral MD) with a significantly impacted quality of life should
be expected, and those patients should be considered with
caution for ablative therapies. Furthermore, MD-hp patients
may have an increased risk of concomitant audiovestibular
symptoms caused by SCC dehiscence syndrome, as suggested
by the higher prevalence (29.4%) of suspected (posterior) SCC
dehiscence on the MRI data. In contrast, SCC dehiscence was
suspected radiologically in only 3.6% of MD-dg patients, mostly
of the superior SCC, which is comparable to the reported overall
prevalence of superior SCC dehiscence in the general population
[3–10% (30–32)]. The epidemiological features associated
with this endotype (predominantly men, familial clustering
of MD, and tendency toward earlier disease onset) support
the hypothesis of a genetic/developmental cause. Therefore,
the endotype’s specific radiological feature (VA bending angle
≥140◦) may be useful for predictive clinical screenings (e.g.,
in family members of MD-hp patients) for this potentially
inheritable inner ear pathology and to prognosticate the risk of
developing MD.
Endotype “ES Degeneration” (MD-dg
Subgroup)
ES degeneration was observed in 76.4% (n = 55; MD-dg group)
of patients. This endotype (VA angle ≤120◦) is radiologically
diagnosed by excluding the hypoplastic endotype (VA angle
≥140◦), but it cannot be distinguished from a normal ES
(VA angle ≤120◦) using the Gd-MRI-based criteria described
herein. Thus, in contrast to the hypoplastic endotype, no
potential prognostic marker for future bilateral manifestation
is available to date. This endotype was exclusively associated
with contralateral “clinically silent” endolymphatic hydrops
(i.e., hydrops without clinical signs of inner ear dysfunction,
particularly without MD). Clinically silent hydrops was observed
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FIGURE 4 | Clinical differences between and within the two MD endotypes. Data from (A–F,H) are also shown in Table 2, data from (G) and (I) were not part of the
initial null hypotheses. Bilat, bilateral; contralat, contralateral; EH, endolymphatic hydrops; ipsilat, ipsilateral; MD, Meniere’s disease; post, posterior; SCC, semicircular
canal; sup, superior; unilat, unilateral; VA, vestibular aqueduct.
in 19.2% of all unilateralMD-dg patients, which is consistent with
previously reported numbers from MRI studies investigating
unilaterally affected MD patients [16.0–23.3% (8, 33)]. Since
clinically silent hydrops reportedly progresses to MD in 33%
of cases (34), MD-dg patients with contralateral hydrops may
have an elevated risk of developing bilateral MD and should
be considered for ablative therapy with caution. However, MD-
dg patients may be generally considered suitable candidates for
ES surgery (decompression or shunting) since the operculum,
which exhibits normal anatomy in these cases, allows its reliable
intraoperative visualization. However, per our previous human
pathology study (6), the extraosseous ES portion is degenerating
in these cases, which calls into question the proposed mode of
function of these treatments. On average, a higher frequency
of vertigo attacks and a more severely impaired vestibular
(caloric) function was associated with this endotype. These
findings may be explained by a supposedly more sudden
manifestation of ES degeneration in the matured inner ear,
as opposed to the developmentally inherent ES hypoplasia. ES
degeneration therefore probably has a more disruptive effect
on vestibular function due to the adult inner ear’s limited
capability to develop compensating homeostatic mechanisms.
In contrast in the developing inner ear, in the presence of
ES hypoplasia, such compensatory function may be established
more efficiently.
Between-Endotype Comparisons With
Little or No Evidence for Group Differences
Of the 28 tested clinical variables, we found weak to no
evidence for endotype differences for 21 variables (Table 2)
and for a longitudinal analysis of hearing loss progression
(Supplementary Figure 1; Benjamini-Hochberg significance: n.
s.). However, our retrospective explorative approach does not
categorically rule out those 21 variables as clinically meaningful,
endotype-segregating features. Specifically, variables such as
migraine headache prevalence, age at first MD symptom onset,
and prevalence of “clinically silent” contralateral endolymphatic
hydrops should, in our view, remain of interest in future
endotyping studies.
Although the migraine headache prevalence did not differ
between endotypes, the overall prevalence of migraine symptoms
in our cohort (59.9%) was similar to that of a previous study
[56% (35)] and considerably higher than the prevalence in the
general population [11–18% (36–38)]. Future studies should
more specifically address questions such as whether migraines
are associated—or even share a common etiopathology—with a
distinct MD endotype.
An earlier age of onset of the first MD symptoms in MD-
hp patients was evident in our previous temporal bone study
(6) (MD-hp: 37.7 ± 19.0 years; MD-dg: 58.1 ± 20.5 years; p =
0.038) but not in the present study (MD-hp: 43.1 ± 8.9 years;
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TABLE 3 | Post-hoc tests.
ES pathology
Clinical feature Category Degeneration Hypoplasia p-value (Bonferroni corrected)
Vertigo Monthly 7 (12.7%) 7 (41.2%) p = 0.048
Daily/weekly or less than once per month 48 (87.3%) 10 (58.8%)
Headache type (males) Migraineous 6 4 p = 0.211
Non-migraineous 5 7
Other 14 5
Family history MD, hearing loss and/or vertigo 8 (15.7%) 7 (41.2%) p = 0.028
No family history 43 (84.3%) 10 (58.8%)
TABLE 4 | Endotype-specific clinical considerations.
Endotype
(patient
subgroup)
Laterality Endotype
frequency
Characteristics/considerations
ES hypoplasia
(MD-hp patients)
Overall 23.6% • Specific radiological feature (VA bending angle ≥140◦)
• Prognostic radiological screening possible
• Possible concomitant SSC dehiscence syndrome
• ES not visualizable for surgical ES enhancement/shunting (*)
Unilateral 16.7% • Very low risk of developing bilateral MD (†)
• Most suitable for vestibular ablative therapy
Bilateral 6.9% • Very high risk of developing bilateral MD
• Avoid performing vestibular ablative therapy (‡)
• Significant impact on auditory/vestibular function and quality of life must be expected
ES degeneration
(MD-dg patients)
Overall 76.4% • Suitable for ES surgery if considered (§)
• Consider average higher frequency of vertigo symptoms, more severe vestibular hypofunction when
establishing treatment
• Consider sequential imaging to rule out ES tumors if symptomatology increases over baseline
fluctuations (‖)
Unilateral 72.2% • “Clinically silent” contralateral EH (19.2%)
• Unknown risk for progression to bilateral disease
• Increased risk to perform vestibular ablative treatment
Bilateral 4.2% • Least frequent endotype, 4.2% of patients
*Considering the anticipated low chance of intraoperatively identifying the operculum (25). (†) equal to the overall risk of developing MD with degenerative ES pathology in the general
population [i.e., 0.15% based on the MD prevalence of 0.2% (26) and a prevalence of degenerative ES pathology of 76.4% among MD patients in the present study]. (‡) upon initial
presentation with clinically unilateral symptoms. (§) due to degenerative changes of extraosseous ES in these patients (6), we consider the rationale for ES surgery questionable. (‖)
according to Kirsh et al. (27). In MD-hp patients, ES hypoplasia sufficiently explains the etiology.
MD-dg: 47.9 ± 12.6; p = 0.152, n. s.). An earlier symptom
onset in the MD-hp group (although not evident in the present
study) could be explained by the likely prenatally determined
hypoplastic ES pathology (7), which presumably renders the
inner ear susceptible to precipitating factors that ultimately cause
MD. In contrast, ES degeneration in MD-dg patients is thought
to be an acquired pathology, possibly associated with age-related
factors, and therefore may explain MD’s tendency to manifest
later in life.
A “clinically silent” (no MD symptoms) endolymphatic
hydrops is a frequent [5–26%, (8, 24, 39)] histological and
radiological entity in the contralateral ears from unilaterally
affected Meniere’s patients, and was in the present study found
exclusively in the MD-dg endotype (19.2%; p = 0.186, n. s.).
The frequent association of this endotype with bilateral hydrops
may suggest limited or still progressing ES degeneration as the
cause for contralateral, clinically silent hydrops, and further
suggests a systemic (e.g. immune-mediated or vascular) etiology
of degenerative ES pathology. Although progression to bilateral
MD was rarely observed in the MD-dg group (4.2%); longer
prospective observations are required to determine whether
clinically silent hydrops represents a precursor lesion of MD.
Patient Subgrouping Approaches in MD
Patient stratification algorithms in MD can be divided
into phenomenology (clinical features)-based “top-down”
algorithms, and etiology (endotype)-based ”bottom-up”
algorithms. Frejo et al. used disease laterality (uni vs.
bilateral) as a principal group classifier, and, in a second
step, applied data mining procedures (cluster analysis) to
identify clinical features (autoimmune disorders, migraine,
MD family history, synchronic vs. metachronic onset of
hearing loss) that segregated five discrete subgroups of uni
and bilateral MD patients, respectively (40, 41). In a follow-up
study, Frejo et al. then used an etiology-based approach and
distinguished two subgroups with different cytokine profiles
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among uni and bilateral MD patients (42). They suggested
an immune-mediated etiology in the subgroup that exhibited
elevated interleucin-1β plasma levels as well as mold-induced
TNF-α secretion. Notably, some subgroups defined by Frejo
et al. share certain group-defining features with the MD-dg
and MD-hp endotypes. Further studies that combine the
described subgrouping/endotyping algorithms will determine
whether the subgroups defined by the different approaches
truly overlap.
Limitations of the Study
The overall study design was retrospective and exploratory.
Thus, for statistical between-group comparisons, an FDR was
chosen that allowed us to identify many endotype-specific
clinical features. Moreover, few patients (n = 72) were
available for this study. Consequently, the statistical power
for some group comparisons was low, and the results from
this investigation should be verified in a larger prospective
cohort study.
For the 20 excluded patients, αexit angles between 120
and 140◦ were measured, or the VA could not be visualized
(Figure 1). Since such αexit values or non-visualization of
the VA were lacking in a previous retrospective MD case
series (n = 64) in which HRCT temporal bone data were
measured (7), we consider this a problem of insufficient
Gd-MRI resolution, likely due to movement artifacts in
individual datasets.
For most included patients, the initial diagnostic test data
(PTA, vestibular diagnostics) were acquired at the time of
diagnosis, whereas for a minority of patients, these initial tests
were performed several months or years after being diagnosed.
This inhomogeneity of the available data is a confounding factor,
particularly in the longitudinal analysis of hearing thresholds
(Supplementary Figure 1).
CONCLUSION
This novel endotype-driven diagnostic approach allowed
distinguishing clinically meaningful MD patient subgroups
with different etiologies and phenotypes. This approach may
(i) help select more homogeneous patient cohorts for future
clinical studies, (ii) refine clinical diagnoses, (iii) improve clinical
decision-making, and (iv) help prognosticate the disease course
in individual patients. The results from this retrospective study
require validation in prospective cohort studies.
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